Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06509490
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-14
Brief Title:
NKG2D CAR-TKD-025 in the Treatment of Advanced NKG2DL Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-center Open Single-arm Clinical Study of the Safety and Efficacy of KD-025 CAR-T Therapy in Advanced NKG2DL Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 single-arm single-center open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL solid tumors
Detailed Description:
This is an open-label dose escalationexpansion study to assess the safety tolerability and efficacy of KD-025 cell infusion in patients with advanced NKG2DL solid tumor In this studythe enrollment of the patients must meet the inclusion and exclusion criteria All subjects will be undergo screening pre-treatment cell product preparationlymphodepleting chemotherapy treatment and follow up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None